ERK1/2 activation attenuates TRAIL-induced apoptosis through the regulation of mitochondria-dependent pathway
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Do Yeon | - |
dc.contributor.author | Lee, Myoung Woo | - |
dc.contributor.author | Lee, Hyun Jung | - |
dc.contributor.author | Noh, Yoo Hun | - |
dc.contributor.author | Park, Soon Cheol | - |
dc.contributor.author | Lee, Moo Yeol | - |
dc.contributor.author | Kim, Kyung Yong | - |
dc.contributor.author | Lee, Won Bok | - |
dc.contributor.author | Kim, Sung Su | - |
dc.date.available | 2019-05-30T06:39:53Z | - |
dc.date.issued | 2006-09 | - |
dc.identifier.issn | 0887-2333 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/24284 | - |
dc.description.abstract | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) functions as an extracellular signal, which triggers apoptosis in tumor cells. In order to characterize the molecular events involved in TRAIL cytotoxic signaling, we attempted to determine the role of extracellular signal-regulated kinase 1/2 (ERK1/2), as well as its downstream targets in TRAIL-treated HeLa cells. Here we demonstrate that TRAIL exposure resulted in the activation of ERK1/2, and the elevation of ami-apoptotic Bcl-2 protein levels. ERK1/2 inhibition with PD98059 promoted cell death via the down-regulation of Bcl-2 protein levels, together with increasing mitochondrial damage, including the collapse of mitochondrial membrane potential, the release of cytochrome c from mitochondria to cytoplasm and caspase activity. These results suggest that the ERK1/2 activation is a kind of survival mechanism to struggle against TRAIL-induced stress condition in early stage, via activating cellular defense mechanisms like as the up-regulation of the Bel-2/Bax ratio, as well as several mitochondrial events. (c) 2006 Elsevier Ltd. All rights reserved. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.title | ERK1/2 activation attenuates TRAIL-induced apoptosis through the regulation of mitochondria-dependent pathway | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.tiv.2006.01.007 | - |
dc.identifier.bibliographicCitation | TOXICOLOGY IN VITRO, v.20, no.6, pp 816 - 823 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000239888500004 | - |
dc.identifier.scopusid | 2-s2.0-33745188454 | - |
dc.citation.endPage | 823 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 816 | - |
dc.citation.title | TOXICOLOGY IN VITRO | - |
dc.citation.volume | 20 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | Apoptosis | - |
dc.subject.keywordAuthor | Bcl-2/Bax | - |
dc.subject.keywordAuthor | Cytochrome c | - |
dc.subject.keywordAuthor | Extracellular signal-regulated kinase 1/2 | - |
dc.subject.keywordAuthor | Tumor necrosis factor-related apoptosis-inducing ligand | - |
dc.subject.keywordPlus | PROTEIN MAP KINASE | - |
dc.subject.keywordPlus | CYTOCHROME-C | - |
dc.subject.keywordPlus | CANCER CELLS | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | BCL-2 | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | LIGAND | - |
dc.subject.keywordPlus | OVEREXPRESSION | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | FAS | - |
dc.relation.journalResearchArea | Toxicology | - |
dc.relation.journalWebOfScienceCategory | Toxicology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.